NewsRoom Articles - Page 46 of 154 - PsychedelicNewsWire (PNW)

TuesdayOct 25, 2022 12:39 pm

Survey Finds No Link Between Psychedelics Use, Cancer Risk

New research has found that the use of psychedelic substances is not linked to the lifetime development of cancer. The investigators’ objective was focused on determining whether there was any truth to research from the 1960s that associated the use of psychedelics to a heightened risk of developing cancer. The research in question was conducted in 1967, with those involved reporting that the use of LSD caused chromosomal damage in white blood cells. Subsequent studies also suggested that exposure to LSD could have carcinogenic potential. For their study, the researchers focused on expanding on a 2021 study that explored the…

MondayOct 24, 2022 12:04 pm

What You Should Know About Colorado’s Psychedelics Ballot Measure

Psychedelic drugs, which can change an individual’s perception and induce hallucinations, are classified under Schedule I of the Controlled Substances Act. Drugs under this schedule are said to have no legitimate medical use and a high potential for abuse. However, numerous studies have shown that psychedelics such as psilocybin mushrooms could actually be useful in the treatment of various mental conditions, including anxiety, depression and post-traumatic stress disorder. Now, the state of Colorado may become the second in the country to permit the use of various psychedelics, which are still prohibited under federal law. The first state in the country…

MondayOct 24, 2022 10:30 am

Silo Pharma Inc.’s (NASDAQ: SILO) Novel Ketamine Formulation Undergoing Safety Evaluation, Pursuing Regulatory Pathway

Ketamine used for decades in large doses for surgical anesthesia, low-dose treatments currently prescribed for pain relief, sedation, and treatment-resistant depression Silo’s time-released ketamine formulation SP-26 currently undergoing safety evaluation, study to uncover maximum tolerated dosing data for future trials SP-26 previously reported positive results in reducing neuropathic nerve pain Silo preparing FDA Pre-Investigational New Drug (“IND”) package for SP-26, intends to pursue 505(b)(2) regulatory pathway Ketamine was approved in the United States in 1970 and has been used extensively for surgical anesthesia. Since then, use of the drug in small doses has expanded considerably to treat pain and treatment-resistant…

FridayOct 21, 2022 2:47 pm

DEA Significantly Increases 2023 Production Quotas for Cannabis, Psychedelics

The U.S. Drug Enforcement Administration (DEA) has proposed a significant increase to the cannabis and psychedelics quota to be produced legally for research in 2023. In a new notice, the federal agency proposed that the new quota for marijuana be increased to 6.7 million grams. This is twice as much as its quota for 2022, which was 3.2 million grams, and more than three times its 2021 quota, which stood at 2 million grams. Increasing the marijuana quota will be easy, especially since the federal agency authorized additional marijuana manufacturers earlier this year. These approved producers can now apply for…

ThursdayOct 20, 2022 2:58 pm

Researchers Show How Psychedelics Bind to Serotonin Receptors Using Virtual Simulation

Scientists have used virtual reality to demonstrate how a psychedelic compound binds itself to a serotonin receptor. Psychedelics are known to target serotonin receptors, in particular the 5-HT2A receptor. 5-HT2A serotonin receptors are normally found along the central nervous system, particularly in regions of the brain essential for cognition and learning. Several antipsychotics, hallucinogens and antidepressants function by targeting serotonin receptors. Abnormal serotonin receptor activity has been linked to a range of psychiatric conditions and disorders, including schizophrenia, depression and drug addiction. Despite all this knowledge, not much was known about how psychedelic molecules bind themselves to the receptor's structure…

WednesdayOct 19, 2022 11:28 am

Study Finds That MDMA May Be Useful in Treating Eating Disorders

An eating disorder is a severe mental health condition that may have damaging emotional and physical consequences for the sufferer. Common eating disorders include bulimia nervosa, binge-eating disorder, and anorexia nervosa. New research has found that MDMA-assisted therapy decreased symptoms of eating disorders in adults suffering from severe PTSD. MDMA, which is commonly known as ecstasy, has demonstrated promise in the treatment of a range of mental health conditions, especially when administered in combination with other therapeutic interventions. The FDA recently granted breakthrough therapy designation for MDMA-assisted therapy for post-traumatic stress disorder, recognizing that it had shown significant improvement over…

TuesdayOct 18, 2022 2:41 pm

Florida Dispensary Uncovers Legal Loophole, Starts Selling Shrooms

Last month, a hemp dispensary located in Florida began to sell psychedelic mushrooms. The dispensary, Chillum, was founded by Carlos Hermida in 2018. Hermida is pushing legal boundaries because psilocybin is still illegal in the county due to its Schedule I classification under the Controlled Substances Act. Drugs under this classification have no legal medical purpose and a high potential for abuse. Other drugs under this schedule include LSD and heroin. Hermida is basing his sales on a legal loophole that allows him to sell Amanita muscaria mushrooms that do not contain psilocybin. This makes them legal under federal law.…

MondayOct 17, 2022 12:04 pm

ALTRD TV Releases Trailer of New Psychedelics Documentary

There has been a seismic shift in public perception toward hallucinogenic drugs such as psilocybin in the past couple of years. After decades of criminalization and little to no research on the effects of psychedelics, the substances have seen a significant surge in interest among the scientific community. Initial research has found that psychedelic drugs seem to have positive effects on mental health, especially when paired with psychotherapy. Researchers have found that psychedelic-assisted psychotherapy can alleviate the symptoms of mental health conditions including treatment-resistant depression, post-traumatic stress disorder (PTSD) and eating disorders. Some have called it the psychedelic renaissance, stating…

FridayOct 14, 2022 1:26 pm

Psychedelics May Be Useful in Treatment of Postpartum Depression

Postpartum depression is a type of depression that women often develop soon after giving birth. It is a complex mix of emotional, physical and behavioral changes and affects roughly 15% of all new mothers. Individuals with postpartum depression experience emotional highs and lows, fatigue, frequent crying, guilt and anxiety, which may make it hard for them to connect with and care for their babies. Other postpartum depression symptoms include feelings of inadequacy, an inability to feel pleasure, low mood, poor concentration and insomnia. Additionally, one in five women with this affliction also consider self-harm with others being plagued with thoughts…

ThursdayOct 13, 2022 11:41 am

Advocates, Legislators in Nevada Call for More Research into Psychedelic Medicine

We have seen interest in psychedelics increasing these last few years as more studies on the benefits of these substances come to light. Thus far, numerous studies have found that substances such as MDMA, psilocybin mushrooms, LSD and mescaline can be useful in the treatment of a range of mental health conditions, including post-traumatic stress disorder, depression and substance-use disorders. A few weeks ago, representatives from a nonprofit advocating for psychedelic therapies for veterans presented a letter to the House Veterans Affairs Committee Meeting in Nevada. The letter pushed for more funding to be allocated for research into psychedelics. In…

News and publishing service for psychedelic related companies

Contact us: 512.354.7000